Tag:

Johnson & Johnson

NJ Dad Dies In Crash, $150K Raised For Widow, Children NJ Dad Dies In Crash, $150K Raised For Widow, Children
NJ Dad Dies In Crash, $150K Raised For Widow, Children Brian Benson, of Scotch Plains, died in a car crash on Wednesday, Sept. 17, according to his obituary from Memorial Funeral Home. He was 46 years old.  Born in New York and raised in Mountain Lakes, Brian was a Rutgers graduate who built a two-decade career in medical device sales with Bausch and Lomb, Johnson & Johnson, and most recently RxSight, his obituary says.  “Brian was a valued member of the RxSight team, bringing nearly 20 years of experience in medical device sales and a deep commitment to his work,” a GoFundMe created by colleague Heather Spiri reads. Brian was de…
Biotech Leader, Mom, Toddler Found Dead In Car Outside PA Home: Coroner Biotech Leader, Mom, Toddler Found Dead In Car Outside PA Home: Coroner
Biotech Leader, Mom, Toddler Found Dead In Car Outside PA Home: Coroner A mother and her 3-year-old son were found dead in a car outside their Quakertown home, the Bucks County Coroner’s Office announced on Tuesday, June 10. Agnes Dawidowicz, 42, and her son Charlie Dawidowicz, 3, were discovered unresponsive in a vehicle parked at their residence on the 2100 block of Barley Drive on Sunday, June 8, authorities said. They were pronounced dead at the scene around 5 p.m. on Sunday, June 8. The causes and manners of death remain under investigation, according to the coroner’s office. Agnes Dawidowicz was a clinical research professional and biotechnology expert w…
Nasal Spray Treating Major Depression Receives FDA Approval For Standalone Use Nasal Spray Treating Major Depression Receives FDA Approval For Standalone Use
Nasal Spray Treating Major Depression Receives FDA Approval For Standalone Use The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of depression, officials said. The FDA granted approval to Spravato (esketamine) as the first monotherapy for adults with treatment-resistant depression, J&J said in a news release on Tuesday, Jan. 21. The decision came after a priority review of clinical data showing significant improvements in depression symptoms as early as 24 hours and sustained progress through four weeks. According to J&J, treatment-resistant depression affects about one-t…